Thursday, 21 Sep 2017

You are here

New insights into the impact of pegloticase in chronic refractory gout

Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions. It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions. 

Abstract THU0438 by Drs. Calabrese, Kavanaugh, Yeo, and Lipsky is a study taking a deep dive into all the infusion reactions encountered during the pegloticase trials where each reaction was adjudicated post hoc and the relationship to whether the patients continued to have their uric acid suppressed (a surrogate of lack of antidrug antibodies) or whether they were failing (a surrogate for the presence of anti-drug antibodies) was explored. The NIAID/FAAN criteria were used to classify infusion reactions. 

The bottom and surprising line is that in the cohort receiving pegloticase q 2 weeks (as recommended in the PI) and who maintained uric acid suppression (i.e., the way we do in clinical practice) the rate of infusion reactions of any kind was 0.5% or 1 in 200 infusions. Furthermore, in this group there were no cases of anaphylaxis.

Lastly, among the 6 cases of ‘anaphylaxis’ among the over 1600 infusions none were fatal or even serious (i.e., requiring advanced support) and 3 of the patients stayed in the trial. It appears that when pegloticase is used correctly it has an excellent safety profile and these data should be reassuring. 

 

L Calabrese, A. Kavanaugh, A Yeo, P Lipsky
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.

1 September 2017: The RheumNow Week in Review

This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.